MedTrace Logo

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

NCT05743426 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-03-30

No results posted yet for this study

Summary

This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.

Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.

Conditions

Interventions

OTHER

Survey

Patient Reported Outcome (PRO) questionnaire

OTHER

Toxicity Assessments

Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Theodore K Yanagihara · Lineberger Comprehensive Cancer Center, The University of North Carolina Chapel Hill

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2036-01-01
Completion
2036-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05743426 on ClinicalTrials.gov